Innovent presents clinical data for bispecific fusion protein IBI363
Innovent Biologics released updated clinical trial metrics at ESMO 2026 for IBI363 TAK 928 a bispecific fusion protein engineered to treat advanced solid malignancies
San Francisco and Suzhou, China, October 26, 2026 - Innovent Biologics, Inc. (HKEX Stock Code: 01801) presented multiple clinical data updates for IBI363, a potential first-in-class PD-1/alpha-biased IL-2 bispecific fusion protein, at the 2026 European Society for Medical Oncology (ESMO) Congress. Developed jointly by Innovent and Takeda, IBI363/TAK-928 showed promising results in lung and gastric cancer studies.
Dr. Hui Zhou, Chief R&D Officer of Innovent, highlighted the broad antitumor potential of IBI363/TAK-928. The company plans to continue advancing its global development and seek new treatment options for patients.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
